Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology

Milad Ashrafizadeh, Shahin Aghamiri, Shing Cheng Tan, Ali Zarrabi, Esmaeel Sharifi, Navid Rabiee, Firoz Babu Kadumudi, Alireza Dolatshahi Pirouz, Masoud Delfi, Kullaiah Byrappa, Vijay Kumar Thakur, Kothanahally S. Sharath Kumar, Yarabahally R. Girish, Farshid Zandsalimi, Ehsan Nazarzadeh Zare, Gorka Orive, Franklin Tay, Kiavash Hushmandi, Alan Prem Kumar, Ceren KaramanHassan Karimi-Maleh*, Ebrahim Mostafavi*, Pooyan Makvandi*, Yuzhuo Wang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

55 Citations (Scopus)
15 Downloads (Pure)


Nanocarriers have received special attention in biomedicine for the treatment of various diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers can improve the potential of contemporary strategies in cancer therapy and also provide new methods for diagnosis and biosensing. The present review focuses on the biomedical application of nanocarriers in the treatment of prostate cancer (PCa), one of the most common urological cancers in men. The chemotherapeutic and radiotherapeutic potentials in PCa may be improved using nanocarriers by providing targeted drug delivery and inducing PCa cells' sensitivity via induction of cell death. Delivery of nucleic acid drugs such as siRNA, shRNA and CRISPR/Cas9 system by nanocarriers in PCa therapy enhances the intracellular accumulation of these therapeutics and increases their efficacy in gene expression regulation. The high proliferation rate and metastasis of PCa cells result in poor prognosis. They may be dually suppressed by nanocarriers, as nanoplatforms facilitate co-delivery of drugs and gene therapeutics in PCa suppression. Selectivity toward PCa cells may be enhanced via surface modification of the nanocarriers to facilitate internalization via endocytosis. In addition to their applications for PCa treatment, nanocarriers mediate the detection of biomarkers for PCa diagnosis.

Original languageEnglish
Article number101532
JournalNano Today
Early online date12 Jul 2022
Publication statusPrint publication - Aug 2022

Bibliographical note

Publisher Copyright:© 2022 Elsevier Ltd


  • Cancer diagnosis
  • Drug sensitivity
  • Gene delivery
  • Prostate cancer
  • Surface modification
  • Therapeutic response


Dive into the research topics of 'Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology'. Together they form a unique fingerprint.

Cite this